The Pharma Letter4d
Semaglutide and tirzepatide potential to transform type 1 diabetes treatment
A recent study published in Diabetes Technology & Therapeutics has demonstrated that the off-label use of semaglutide and ...
Millions of people are taking compounded weight loss drugs. Now, they're about to disappear.
Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...
The GLP-1 shortages are over. What happens next?
Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now soon they may be unavailable to most.
AOL.co.uk2d
The GLP-1 shortages are over. What happens next?
Tirzepatide is approved by the Food and Drug ... Novo Nordisk and Eli Lily. So prescribing these purportedly “custom” compounded injections is “a practice that is worrisome, and it’s ...
pharmaphorum3d
The race for obesity drug assets heats up
The former’s Wegovy (semaglutide) product saw sales grow from 2.4 billion in Q4 2022 to 9.6 billion Danish kroner (DKK) in Q3 2023, and Lilly’s Mounjaro (tirzepatide) manage sales of $1.4 ...
Eli Lilly plans to launch weight-loss drug in emerging markets this year
Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...
Yahoo Finance5d
Off-label use of semaglutide and tirzepatide shows promise in type 1 diabetes
A recent study published in Diabetes Technology & Therapeutics has demonstrated that off-label use of semaglutide and tirzepatide leads to significant reductions in glycated haemoglobin (HbA1c ...